Received Mar 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | 2 | 026L12B | IM |
Suspected blood clot in shoulder/Had a blood clot that was formed in arm and then it traveled to heart; suspected minor heart attack; This spontaneous case was reported by a consumer and describes the occurrence of DEEP VEIN THROMBOSIS (Suspected blood clot in shoulder/Had a blood clot that was formed in arm and then it traveled to heart) and MYOCARDIAL INFARCTION (suspected minor heart attack) in a 4-decade-old male patient who received mRNA-1273 (Spikevax) (batch nos. 026L12B and 627L21A) for COVID-19 prophylaxis. Previously administered products included for Product used for unknown indication: MMR vaccine (Patient received vaccination when the patient was a kid), Herpes Simplex Virus (The patient was unsure whether they had received vaccination 1 or 2. However, it was believed to be HSV-2 and as vaccine or viral interference made the patient uncertain about whether the vaccine had already provided protection.). Past adverse reactions to the above products included No adverse effect with Herpes Simplex Virus and MMR vaccine. In March 2022, the patient received first dose of mRNA-1273 (Spikevax) (Intramuscular use) 1 dosage form. In April 2022, received second dose of mRNA-1273 (Spikevax) (Intramuscular use) dosage was changed to 1 dosage form. On an unknown date, the patient experienced DEEP VEIN THROMBOSIS (Suspected blood clot in shoulder/Had a blood clot that was formed in arm and then it traveled to heart) (seriousness criterion medically significant) and MYOCARDIAL INFARCTION (suspected minor heart attack) (seriousness criterion medically significant). At the time of the report, DEEP VEIN THROMBOSIS (Suspected blood clot in shoulder/Had a blood clot that was formed in arm and then it traveled to heart) and MYOCARDIAL INFARCTION (suspected minor heart attack) outcome was unknown. No concomitant medications provided by the reporter. The patient unable to remember how long after the vaccine the patient had the blood clot. The patient felt that the blood clot in shoulder and had a sense that it would travel to patient heart, which eventually did, leading to minor heart attack. It was also reported that the patient felt that the blood clot in shoulder and had a sense that it would travel to heart. It was reported that the patient went through pain and suffering, and it was clarified that the patient had a heart attack. However, the patient did not experience significant chest pain, did not go to hospital and had no treatment for it. The patient consulted about the symptoms with doctor after a week of incident. The doctor conducted the tests and suggested to the patient that if the patient has a blood clot, then patient would have felt significant pain with it. The reporter enquired whether a post-vaccination blood clot could have been influenced by the patient's lifestyle, as the patient had experienced a blood clot followed the vaccination. The reporter also raised concerns about the participation of infants and children in vaccine studies, noting that they had suffered adverse events and questioning the ethics and legality of such involvement, including whether it constituted child abuse. No treatment medications provided by the reporter. Most recent FOLLOW-UP information incorporated above includes: On 25-Feb-2026: Live non-significant follow-up received in which new reference number was added. On 25-Feb-2026: Live Significant follow-up received in which new event of Heart attack was added, case narrative was updated, and new reference number was added. On 25-Feb-2026: Live non-significant follow-up received, and new reference number was added. On 25-Feb-2026: Live non-significant follow-up received, and new reference number was added. On 25-Feb-2026: Live significant follow-up received in which other Relevant History was added, suspect drug coding was updated, and dosage regimen was updated. New reference number was added. On 26-Feb-2026: Live non-significant follow-up received in which case narrative was updated and new reference number was added. On 27-Feb-2026: Live significant follow-up received in which suspect product batch and lot number was added. New reference number was added.; Reporter's Comments: The benefit-risk relationship of product is not affected by this report.